Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Citi continue to see upside to Eli Lilly & Co.'s (LLY) 'already rich' valuation
November 2, 2023 11:11 AM EDTCiti analyst Andrew Baum said in a note Thursday that the Mounjaro beat for Eli Lilly & Co. (NYSE: LLY) goes on after the companys solid third-quarter results, which were boosted by the drug.
Baum reiterated a Buy rating and $675 price... More
Eli Lilly (LLY) falls after cutting full-year profit forecast
November 2, 2023 6:45 AM EDTEli Lilly (NYSE: LLY) shares fell in early Thursday trade after the company lowered its full-year outlook.
Eli Lilly now projects an EPS in the range of $6.50 to $6.70, which fell below the consensus estimate of $6.72.
"Lilly had another strong quarter in Q3... More
Eli Lilly & Co. (LLY) Tops Q3 EPS by 30c; Trims Outlook
November 2, 2023 6:31 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $0.10, $0.30 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $9.5 billion versus the consensus estimate of $8.97 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2023 EPS of $6.50-$6.70, versus the... More
